title: Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation.
abstract: BACKGROUND
  We evaluated the possible advantages of a docetaxel (DCT) rechallenge strategy in metastatic castration-resistant prostate cancer (mCRPC) patients, also given the possible earlier positioning of this treatment option in the modern scenario.
  
  
  METHODS
  All mCRPC patients planned for DCT chemotherapy rechallenge in our institutions were evaluated.
  
  
  RESULTS
  Of 128 patients, 98 achieved disease control on the initial DCT round. After a treatment holiday of 8.3 months, the 98 responsive patients underwent a second DCT round, with 56 cases achieving again disease control. After a 5.7-month off-treatment period, 32 of these cases underwent a third DCT round, and 16 responded. Lastly, after a further 4.2-month treatment holiday, eight patients underwent a fourth DCT round and two responded. Median time to definitive disease progression for the whole population was 16.4 months.
  
  
  CONCLUSIONS
  Rechallenge with DCT may be considered a suitable treatment option for mCRPC patients recurring after a successful DCT chemotherapy. The interest in this strategy may be increased because of the showed efficacy of early DCT chemotherapy in patients with bulky disease (CHAARTED study) and the potential lower efficacy of the new hormonal agents abiraterone acetate and enzalutamide when used in a immediate sequencing.
authors.affiliation: Medical Oncology, Ospedale San Donato, Azienda USL8, Istituto Toscano Tumori (ITT), Arezzo, Italy.
authors.forename: Sergio
authors.initials: S
authors.lastname: Bracarda
authors.affiliation: Medical Oncology, Ospedale S Maria, Terni, Italy.|Medical Oncology, Ospedale della Gruccia, Azienda USL8, Istituto Toscano Tumori (ITT), Arezzo, Italy.
authors.forename: Claudia
authors.initials: C
authors.lastname: Caserta
authors.affiliation: Medical Oncology, Azienda Ospedaliera Universitaria di Perugia, Perugia, Italy.
authors.forename: Luca
authors.initials: L
authors.lastname: Galli
authors.affiliation: Medical Oncology, Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori (ITT), Pisa, Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Carlini
authors.affiliation: Medical Oncology, IRCCS Regina Elena, Rome.
authors.forename: Ilaria
authors.initials: I
authors.lastname: Pastina
authors.affiliation: Medical Oncology, Ospedale San Donato, Azienda USL8, Istituto Toscano Tumori (ITT), Arezzo, Italy.
authors.forename: Michele
authors.initials: M
authors.lastname: Sisani
authors.affiliation: Medical Oncology, Ospedale Misericordia, Istituto Toscano Tumori (ITT), Grosseto, Italy.
authors.forename: Simona
authors.initials: S
authors.lastname: Scali
authors.affiliation: Medical Oncology, Ospedale San Donato, Azienda USL8, Istituto Toscano Tumori (ITT), Arezzo, Italy.|Medical Oncology, Ospedale della Gruccia, Azienda USL8, Istituto Toscano Tumori (ITT), Arezzo, Italy.
authors.forename: Alketa
authors.initials: A
authors.lastname: Hamzaj
authors.affiliation: Medical Oncology, Azienda Ospedaliera Universitaria di Perugia, Perugia, Italy.
authors.forename: Lisa
authors.initials: L
authors.lastname: Derosa
authors.affiliation: Medical Oncology, Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori (ITT), Pisa, Italy.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Felici
authors.affiliation: Medical Oncology, Ospedale della Gruccia, Azienda USL8, Istituto Toscano Tumori (ITT), Arezzo, Italy.
authors.forename: Marta
authors.initials: M
authors.lastname: Rossi
authors.affiliation: Medical Oncology, Ospedale San Donato, Azienda USL8, Istituto Toscano Tumori (ITT), Arezzo, Italy.
authors.forename: Amelia
authors.initials: A
authors.lastname: Altavilla
authors.affiliation: Medical Oncology, IRCCS Regina Elena, Rome.
authors.forename: Aldo
authors.initials: A
authors.lastname: Chioni
authors.affiliation: Medical Oncology, Ospedale della Gruccia, Azienda USL8, Istituto Toscano Tumori (ITT), Arezzo, Italy.
authors.forename: Verena
authors.initials: V
authors.lastname: De Angelis
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018450:Disease Progression; D000077143:Docetaxel; D005500:Follow-Up Studies; D006801:Humans; D057194:Intention to Treat Analysis; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D019233:Retreatment; D012189:Retrospective Studies; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel
keywords: docetaxel; docetaxel rechallenge; intermittent chemotherapy; prostate cancer